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Abstract
Precision health relies on the ability to assess disease risk at an individual level, detect early 
preclinical conditions and initiate preventive strategies. Recent technological advances in omics 
and wearable monitoring enable deep molecular and physiological profiling and may provide 
important tools for precision health. We explored the ability of deep longitudinal profiling to make 
health-related discoveries, identify clinically relevant molecular pathways, and impact behavior in 
a prospective longitudinal cohort (n = 109) enriched for risk of type 2 diabetes mellitus (DM). The 
cohort underwent integrative Personalized Omics Profiling (iPOP) from samples collected 
quarterly for up to 8 years (median 2.8 years) using clinical measures and emerging technologies 
including genome, immunome, transcriptome, proteome, metabolome, microbiome, and wearable 
monitoring. We discovered over 67 clinically actionable health discoveries and identified multiple 
molecular pathways associated with metabolic, cardiovascular and oncologic pathophysiology. We 
developed prediction models for insulin resistance using omics measurements illustrating their 
potential to replace burdensome tests. Finally, study participation lead the majority of participants 
to implement diet and exercise changes. Altogether, we conclude that deep longitudinal profiling 
can lead to actionable health discoveries and provide relevant information for precision health.
Introduction
Precision health and medicine are entering a new era where wearable sensors, omics 
technologies, and computational methods have the potential to improve health and lead to 
mechanistic discoveries1,2. Emerging technologies such as longitudinal multi-omics 
profiling combined with clinical measures can comprehensively assess health and identify 
deviations from healthy baselines which may improve disease risk prediction and early 
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detection. Connecting longitudinal multi-omics profiling with clinical assessment is also 
important in developing a new taxonomy of disease based on molecular measures1.
Despite this promise, few studies have leveraged emerging technologies and longitudinal 
profiling to manage health and identify disease markers. Previous efforts included our study 
of a single individual in which longitudinal multi-omics profiling over 14 months captured 
the individual’s transition to diabetes on a deep molecular level3. A recent study of 108 
individuals followed for 9 months using various omic technologies revealed several health-
related findings4. A cross-sectional study used genome sequencing, metabolomics and 
advanced imaging to identify individuals at risk for age-related chronic disease5. These 
studies either had limited sample size, lacked meaningful longitudinal profiling, or 
performed only limited analysis of health information. We have also demonstrated utility in 
using wearable devices to detect infections2 and identify early glucose dysregulation6 and 
population-based studies are underway to potentially to detect arrhythmias7.
In this study, we longitudinally profiled 109 participants at risk for DM (Fig. 1), performing 
quarterly clinical laboratory tests and multi-omics assessments. In addition, individuals 
underwent exercise testing, enhanced cardiovascular imaging and physiological testing, 
wearable sensor monitoring, and completed various surveys.
The study objectives were threefold. We first evaluated the usefulness of emerging 
technologies in combination with standard and enhanced clinical tests to detect diseases 
early. We then characterized multi-omics associations with clinical pathophysiologies 
including glucose and insulin dysregulation, inflammation, and cardiovascular risk; 
evaluated the ability of multi-omics measures to predict insulin resistance and response to 
glucose load. Lastly, we examined how participation affected health habits.
Results
Summary of Research Design & Cohort
A 109-person cohort enriched for individuals at risk for DM (Table 1, Extended Data Fig. 
1a) underwent quarterly longitudinal profiling for up to eight years (median 2.8 years) using 
standard and enhanced clinical measures and emerging assays. (Fig. 1). Emerging tests 
included molecular profiling of the genome, gene expression (transcriptome), proteins 
(proteome), immune proteins (immunome), small molecules (metabolome) and gut microbes 
(microbiome), and wearable monitoring including continuous glucose monitoring (CGM)6. 
Our study was designed to capture transitions from normoglycemic to preDM and from 
preDM to DM. Thus, in addition to standard measures such as fasting plasma glucose (FPG, 
reflects steady state glucose metabolism8) and glycated hemoglobin (HbA1C, reflects 3 
month average glucose), enhanced measures included the oral glucose tolerance test (OGTT, 
reflects response to glucose load9) with insulin secretion assessment (beta-cell function) and 
the modified insulin suppression test (SSPG, a measure of peripheral insulin resistance). We 
also performed enhanced cardiovascular profiling including vascular ultrasound, 
echocardiography, cardiopulmonary exercise testing and cardiovascular disease protein 
markers. Technical details are provided in the methods and our integrated Human 
Microbiome Project (iHMP) paper by Zhou et al. (submitted). The full details of clinical 
Rose et al. Page 3
Nat Med. Author manuscript; available in PMC 2019 November 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
laboratory measures, immune proteins and cardiovascular biomarkers are provided in Table 
S0. The study was approved by the Stanford University Institutional Review Board (IRB 
23602) and all participants consented.
The mean age of iPOP participants at initial enrollment was 53.4 ± 9.2 years old. 
Demographic, baseline health, and family history characteristics are shown in Table S1. 
Genetic ancestry analysis (n = 72) using the 1000 Genomes data10 shows that individuals 
mapped to expected ancestral populations (Extended Data Fig. 1b).
Over the study course, we found over 67 major clinically actionable health discoveries 
spanning metabolism, cardiovascular disease, oncology and hematology, and infectious 
disease (Table S2). We demonstrate ways in which longitudinal multi-omics measures can 
be used to advance precision medicine, including by illuminating biological pathways 
underlying standard measures, predicting burdensome physiological measurements, and 
enabling exploration of mechanisms of disease onset.
Metabolic Health Profiling
At entry, participants reported their DM status. Of the 86 participants (78.9%) who did not 
report preDM or DM, one had a diagnosis of DM in their health record, one had a DM-range 
HbA1C and 43 individuals (39.4%) had labs in the preDM range at entry (Fig. 2a). During 
the study, eight more individuals converted to DM as assessed by a clinical diagnosis of DM 
(n = 4), starting a diabetic medication after a diabetic range laboratory result (n = 3), and/or 
if they had labs in the diabetic range (n = 6) at more than one time point. Five additional 
participants developed laboratory abnormalities in the diabetic range at one time point, and 
12 developed abnormalities in the prediabetic range. In addition, 2 participants had diabetic 
range CGM measurements (> 200 mg/dL) who were normoglycemic on FPG, HbA1C and 
OGTT (Table S3) indicating that these individuals have glucose dysregulation that is most 
easily assessed using CGM.
Value of exome sequencing—Exome sequencing11 provided relevant information for 
diabetes management. Most notable was the discovery of a hepatic nuclear factor 1A 
mutation, pathogenic for Maturity-Onset Diabetes of the Young (MODY), in a participant 
with DM. This discovery has implications for medications12 and the individual decided to 
have the children tested. Excluding a MODY mutation was valuable to a second participant. 
Other discoveries are listed in Table S2.
Enhanced metabolic profiling—DM is a complex disease with various underlying 
pathophysiologies including insulin resistance, pancreatic beta-cell dysfunction and 
abnormal gluconeogenesis13, which can have differential effects on standard measures. Over 
the study course, 22 participants had at least one test result in the diabetic range (Fig. 2b) but 
few (n = 2) had concordance of all three measures. When performed simultaneously, FPG-
HbA1C and FPG-OGTT were in agreement 65.2% and 52.6% of the time, respectively 
(Extended Data Fig. 2a,b), highlighting that DM status varies depending on the assessment 
method. Most participants also underwent insulin sensitivity assessment (n = 69); 55% were 
resistant (SSPG ≥ 150 mg/dl). In addition, insulin secretion during OGTT was assessed in 
61 participants using the C-peptide deconvolution method14 and the glucose disposition 
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index (DI) was calculated15. Based on OGTT measurements, participants were categorized 
in three groups: normoglycemic, impaired fasting glucose only (IFG only) and impaired 
glucose tolerance (IGT). We observed large inter-individual variability in insulin levels, 
insulin resistance and DI between groups (Fig. 2c). Participants with IGT had higher insulin 
levels 120 min post-OGTT test, higher SSPG (more insulin resistant) and a lower DI. 
Cluster analysis of the longitudinal pattern of insulin secretion rates during OGTTs 
demonstrated four insulin secretion groups: early, intermediate, late and very late (Fig. 2d). 
Each cluster was heterogeneous in terms of OGTT status, DI, insulin resistance status and 
maximum insulin level and demonstrated no consistent pattern of molecular enrichment, 
indicating high heterogeneity in glucose dysregulation.
We also searched for multi-omics molecular associations with the disposition index across 
the cohort and found 109 significant molecules (FDR < 0.1) (Table S4). HbA1C (FDR = 
2.0E-03) and FPG (FDR = 4.9E-02) were negatively associated with DI as expected from 
previous reports showing increased FPG and HbA1C with beta-cell dysfunction16,17. We 
found that DI was strongly negatively associated with leptin (FDR=1.6E-07) and GM-CSF 
(FDR=7.2E-07) which are known regulators of energy homeostasis and inflammation 
signaling18,19. GM-CSF (p = 1.5E-07) and leptin (p = 3.3E-07) were also the two analytes 
that were most strongly positively associated with body mass index in our cohort and were 
positively associated with hsCRP illustrating their connection to inflammation and obesity. 
In the DI correlation network, leptin and GM-CSF were correlated with various lipid classes 
including an inverse correlation with androgenic steroids, and a positive correlation with 
sphingolipids and sphingosines, free fatty acids and glycerophospholipids highlighting their 
importance in lipid metabolism20 (Fig. 2e, Table S5).
Longitudinal course & mechanistic insights—A study strength is its dense 
longitudinal sampling approximately every 3 months. Based on individual longitudinal 
HbA1C trajectories, participants were classified into 6 categories (Extended Data Fig. 2c). 
Notably it was common for participants’ HbA1C to alternate between normal-preDM (n = 
21) and preDM-DM range (n = 8). No one stayed exclusively within the DM range due to 
good diabetes control with lifestyle and medications. Consistent transitions from normal to 
preDM (n = 5) and from preDM to normal HbA1C (n = 10) were less common.
Close evaluation of individual trajectories of participants with new diabetes (n = 9) revealed 
additional insights. Individual trajectory analysis revealed that participants followed multiple 
pathways to diabetes (Fig. 3a-c, Extended Data Fig. 3, Table S3). Some participants’ (n = 2) 
first abnormality was DM-range OGTT (Fig 3a, Extended Data Fig. 3a), others (n = 3) had 
elevated FPG (Fig. 3b, Extended Data Fig. 3b,c), the remainder (n = 4) had a DM-range 
HbA1C (Extended Data Fig. 3d,e) or abnormalities in multiple measures (Fig. 3c, Extended 
Data Fig. 3f). Interestingly, diabetic range labs followed viral infections3 in one participant 
(Fig. 3c). Also, one participant with a single DM lab improved their SSPG with diet and 
exercise (Extended Data Fig. 3g) and never had a second DM range lab during the study.
Progression to DM was associated with weight gain and decreased gut microbiome diversity 
(Shannon) in 2 of 8 participants (Fig. 3a,b, Extended Data Fig. 4a,b). In both cases, the 
phylum Bacteroidetes proportion was increased at the time point of lowest diversity to the 
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detriment of beneficial bacteria such as the genus faecalibacterium (Extended Data Fig. 
4c,d,e). Using linear mixed models to account for repeated measures, we evaluated the 
relationship between microbiome diversity and SSPG, FPG and HbA1C and found an 
inverse relationship with diversity that was strongest with SSPG (p = 1.5E-04) (Table S6). 
We then performed longitudinal mixed model analysis to understand changes in diversity 
over time (Table S7). SSPG accounted for 28% of the between-person Shannon variance 
highlighting the importance of insulin resistance in microbiome diversity. The majority of 
Shannon variance was intra-individual (76.8%) and adding the Bacteroidetes phylum 
proportion to the model including its interaction with time accounted for 41% of the 
remaining within-person variance, consistent with the relationship observed in the individual 
profiles between Bacteroidetes proportion and diversity.
Longitudinal evaluation of all data related to glucose and insulin regulation provided insights 
into mechanism. For instance, the person in Fig. 3c had a normal SSPG despite a diabetic 
range OGTT, FPG and HbA1c. Although elevated OGTT is commonly thought to result 
from increased peripheral resistance or decreased insulin production, this participant had 
elevated insulin production with a delayed response trajectory, possibly reflecting delayed 
insulin release (Table S3). Other mechanistic insights are provided in Table S3. In 
conclusion, participants developed diabetes through different pathways and our detailed 
characterization provides potential hypotheses regarding individual underlying mechanism 
of glucose dysregulation which is a goal of precision medicine.
Multi-omic dimensions of glucose metabolism & inflammation—We examined 
the underlying relationships between glucose (FPG, HbA1C) and inflammation (hsCRP) 
levels and multi-omics measurements at healthy time points (healthy-baseline models) and 
with relative changes for all time points (dynamic models) using linear mixed models. The 
two analyses are complementary since the healthy-baseline models highlight the stable 
relationships between measures and dynamic models highlight common associations with 
change.
As expected, the healthy-baseline analysis demonstrated that HbA1C and FPG strongly 
associated with each other and the ‘glucose homeostasis’ pathway (Fig. 3d, Extended Data 
Fig. 5, Tables S8-13). Although the two measures had many common associations, 
particularly with metabolites including lipids (free fatty acids and total triglyceride level 
(TGL)) and amino acids as previously reported21, many analytes were exclusively associated 
with FPG or HbA1C highlighting the differential underlying biology captured by both 
measures. While HbA1C associated with unsaturated fatty acid (FDR = 8.2E-04) and 
glycerophospholipid metabolism (FDR = 2.88E-03), FPG associated with amino acid (FDR 
= 7.4E-04) and bile acid metabolism (FDR = 4.6E-03).
The dynamic model analysis revealed more commonalities between changes in glucose 
measures and inflammation (Fig. 3d,e, Extended Data Fig. 5, Tables S14-19). As expected, 
hsCRP positively associated with inflammatory proteins including MIG (FDR = 1.4E-24) 
and IP10 (FDR = 3.9E-22) as well as immune pathways including ‘complement activation’ 
(FDR = 8.7E-16), ‘innate immune system’ (FDR = 8.3E-14) and ‘oxidative damage’ (FDR = 
3.0E-06). Interestingly, both HbA1C and hsCRP positively associated with total white blood 
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cells, monocytes and neutrophils consistent with previous findings22. In addition, hepatocyte 
growth factor (HGF) associated with HbA1C and hsCRP, consistent with its role in glucose 
metabolism and modulation of inflammatory response23. We also observed that FPG and 
HbA1C both associated with ‘leukotriene biosynthesis’ which contributes to inflammation 
and leads to insulin resistance24. HbA1C also associated with additional pathways related to 
lipid metabolism including ‘plasma lipoprotein assembly’ and ‘chylomicron assembly’ 
which further demonstrates the connection between inflammation, lipid metabolism and 
metabolic regulation of glucose.
Multi-omics prediction of SSPG & OGTT—The modified insulin suppression test is a 
clinically important direct measure of peripheral insulin resistance but is expensive, labor-
intensive, and requires six hours. The two-hour OGTT is a sensitive test for diabetes and is 
less expensive, but still inconvenient. Thus, we evaluated how well multi-omics 
measurements could predict the results of these tests. Using a Bayesian network algorithm, 
we first identified highly predictive features followed by ridge regression modeling using 
these features25,26. The SSPG prediction model using all omes achieved a cross-validated R2 
of 0.87 (final model mean square error (MSE) 0.16) compared to an R2 of 0.59 (MSE 0.55) 
using clinical data only (Fig. 3f, Table S20). We also compared predictive models using 
clinical data plus each single ome and found that the transcriptome (R2 0.88, MSE 0.15), 
metabolome (R2 0.80, MSE 0.31) and microbiome models (R2 0.78, MSE 0.26) had the best 
predictive accuracy for SSPG. Similarly, the multi-omic prediction model for OGTT (R2 
0.71, MSE 0.24) was superior to the clinical data only model (R2 0.42, MSE 0.71) (Fig. 3f, 
Table S21). The transcriptome had the best predictive accuracy of the single ome models (R2 
0.62, MSE 0.30). Molecules that were found to be consistent across multiple SSPG models 
included the TGL/HDL (high-density lipoprotein) ratio, the protein IL-1RAP; the lipid 
Hexosylceramide (HCER)(24:0), the MAP3K19 transcript and a Ruminococcaceae family 
microbe. The relationship between insulin resistance and TGL/HDL ratio has already been 
described27 and other measures are emerging28-30. There was little overlap between SSPG 
and OGTT predictors supporting that these measures reflect different underlying biology. 
The increased predictive performance with multi-omics measurements compared to clinical 
labs alone illustrates the benefit of multi-omics data.
Other metabolic disorders—Other clinical abnormalities were observed in sodium, 
potassium and liver enzymes (ALT) as well as microalbuminuria and macroalbuminuria 
(Table S2). People with preDM and DM are at higher risk for liver steatosis and 
albuminuria. Using the American Gastroenterological Association (AGA) Guidelines 31 for 
health normal references (males: 25–33 IU/L; females: 19–25 IU/L) revealed that the 
majority of participants (83%) had at least one elevated healthy visit ALT and 41% had 
elevations at all healthy time points. Given the AGA recommendations for ultrasound 
screening31, our findings suggest that screening for nonalcoholic fatty liver disease is 
indicated in the majority of our population.
One participant was a significant outlier in gene expression related to toxicity pathways 
including oxidative stress and hepatic abnormality pathways (Extended Data Fig. 6a, Zhou 
et al., submitted). The participant had mild elevation in ALT accompanied by increases in 
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bile acids and glutamyl dipeptides (Extended Data Fig. 6b), and was later diagnosed with 
mild hepatic steatosis. However, many participants had mild ALT elevations and at least five 
had hepatic steatosis, thus these clinical findings are not sufficient to explain the RNA-seq 
outlier status. Although multiple omics and other measures point to aberrant hepatic 
function, clinical manifestations were unclear and this individual will be tracked for hepatic 
abnormalities.
Cardiovascular Health Profiling
Atherosclerotic cardiovascular disease (ASCVD) is a major cause of mortality and 
morbidity associated with insulin resistance and DM32. We assessed the American Heart 
Association ASCVD risk score, estimating 10-year risk of heart disease or stroke on all 
participants33 at study entry. We also followed longitudinal trajectories of dyslipidemia and 
systemic hypertension. Enhanced cardiovascular profiling was performed on 43 participants 
and included i) vascular ultrasound and echocardiography to assess for subclinical 
atherosclerosis, arterial stiffness or early stage adverse ventricular remodeling or dysfunction 
and ii) emerging biomarkers assessment to interrogate oxidative stress, inflammation, 
immune regulation, myocardial injury and myocardial stress pathways34-36.
Cardiovascular risk profiles—At study entry, 24 patients (22.6%) had an ASCVD risk 
score ≥ 7.5%, a threshold often used to guide primary prevention33 (Fig. 4a). Total 
cholesterol and blood pressure measurements indicate that self-report underestimated the 
prevalence of dyslipidemia (Fig. 4b) and 18 participants learned they had Stage II 
hypertension during the study.
Clinical discoveries through enhanced clinical phenotyping—Wearable and 
cardiovascular imaging led to important clinical discoveries. Wearable heart rate monitoring 
identified two participants with nocturnal supraventricular tachycardia, leading to the 
diagnosis of obstructive sleep apnea in one and atrial fibrillation secondary to sleep apnea in 
the other. In the subgroup of participants who had enhanced cardiovascular imaging studies, 
we discovered two major health findings: one cardiac finding associated with a pathogenic 
mutation in the RPM20 gene, and one non-cardiac finding (Table S2). Fitness assessment 
using percent predicted oxygen consumption (maximal oxygen consumption relative to a 
healthy person of the same age and weight) identified three participants with values below 
70% suggestive of a reduction in exercise capacity which has been associated with poorer 
health outcomes37 (Extended Data Fig. 7a). Subclinical atherosclerosis was found in six 
participants leading to a recommendation to increase statin dose (Extended Data Fig. 7b). 
Overall, there were 15 important clinical findings through these enhanced tests (Table S2).
Cardiovascular events, pharmacogenomic & transcriptomic findings—Five 
participants had cardiovascular events during the course of the study including stroke (n = 
3), unstable angina (n = 1) and stress-induced cardiomyopathy (n = 1). All had elevated 
hsCRP levels prior to their event. Two participants with incident strokes had 
pharmacogenomic variants that could partially explain suboptimal response to the chosen 
therapy. One participant on aspirin for stroke prevention had a COMT (catechol-o-
methyltransferase) Val/Val genotype (rs4680) which has a 85% increased risk of 
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cardiovascular events in female aspirin users compared to placebo controls38. The other 
participant with incident stroke was an intermediate clopidogrel metabolizer phenotype 
(CYP2C19*2 (rs4244285)/CYP2C19*17 (rs12248650) and had a second stroke while on 
clopidogrel. Intermediate metabolizers of clopidogrel were common in our study (31/88 
(35%)) and 4/88 (4.5%) were poor metabolizers. Additional pharmacogenomic variants 
related to the common cardiovascular medications statins and coumadin were found in 26 
and 30 participants, respectively (Table S22).
We also analyzed 14 of 32 genes associated with stroke and stroke types39 which were 
robustly detected in our RNA-seq dataset. Outlier analysis revealed that two of the five 
participants with cardiovascular events had the highest composite Z-scores at clinically 
relevant time points including post-stent placement (Z-score = 33.2, FDR = 6.9E-06), mid-
infection (Z-score = 40.4, FDR = 3.2E-09) for one participant and transition to diabetes (Z-
score = 30.1 and 24.1) for the other (Extended Data Fig. 7d,e). Thus, expression levels of 
genes related to stroke were outliers and associated with significant health issues.
Multi-omics analysis of ASCVD risk—We evaluated multi-omics measures associated 
with adjusted ASCVD risk score using Spearman correlation (Table S23), and constructed a 
correlation network. This analysis revealed relationships between clinical and omics 
measures such as monocytes bridging cytokines and complement proteins, and triglyceride 
and cholesterol measures linking to apolipoproteins (Fig. 4c, Table S24). Among immune 
proteins, the interferon-gamma pathway (MIG, IP10, interleukin (IL)-2, vascular endothelial 
growth factor alpha and HGF) were strongly associated with the ASCVD risk score. The 
interferon-gamma pathway has been recently found to play a key role in atherosclerosis 
based on population based studies40-44. IL-2 has been shown to be associated with 
atherosclerosis through its role in T-cell mediated inflammation44. HGF is involved in the 
survival of endothelial cells and is emerging as a risk factor of outcome41,42. Our network 
also highlighted several molecules that are emerging in cardiovascular disease including 
complement and free fatty acids as well as γ-glutamyl-ε-lysine (reported in diabetic 
nephropathy), hypoxanthine, methylxanthine (associated with coffee consumption) and bile 
acids45-47.
In participants who underwent cardiovascular imaging, we also performed a correlation 
network analysis that shows how ASCVD risk, enhanced imaging and selected circulating 
protein markers associate together (Extended Data Fig. 7c, Table S1). ASCVD score was 
closely related to HGF, which itself was closely related to inflammatory cytokines IL-1B 
and IL-18, part of the inflammasome complex. Exercise capacity as assessed with peak VO2 
was closely associated with GDF-15, a transforming growth factor which is associated with 
cardiovascular mortality risk48 and leptin, a hormone that regulates appetite49. These 
findings demonstrate an interaction between inflammation and ASCVD risk and suggest 
new opportunities for personalized risk stratification, beyond those currently available.
Oncological, Hematological & Immune Profiling
Exome sequencing also led to several important oncological, hematological and immune-
related clinical discoveries. Eight participants learned they had clinically actionable genetic 
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variants associated with increased oncologic risk, such as APC, SDHB, BRCA1, MUTYH, 
CHEK2 and hematologic risk (PROS1) (Table S2). In one case, follow-up screening led to 
discovery of an early-stage papillary thyroid cancer, and the participant was able to elect 
thyroid preserving surgery due to early detection.
B-cell lymphoma discovery & longitudinal outlier analysis—Abdominal 
ultrasound imaging revealed splenomegaly and large para-aortic lymph nodes in one 
participant (Fig. 5a); immediate clinical work-up (Fig. 5b,c, Table S3) led to diagnosis of B-
cell lymphoma. Longitudinal omics outlier analysis revealed a striking increase (> 5-fold) in 
the cytokine MIG that started over a year prior to diagnosis and returned to baseline after 
treatment (Fig. 5d). Its early elevation suggests possible utility as an early biomarker, 
consistent with other studies50-52. Although likely important in a number of cancers53, our 
data demonstrates MIG’s utility as a longitudinal marker of disease. A notable decrease in 
histidine-rich glycoprotein was also evident at diagnosis (Table S25), consistent with its 
previously reported role in inhibiting tumor growth and metastasis54,55.
The functional association network using proteins which were in the 95th percentile at the 
time of diagnosis relative to all the healthy visits in the study illustrates the central role of 
MIG in orchestrating other cytokines, namely ENA78, IL17A and VCAM1 (Fig. 5e). 
Pathways involved in inflammation/immune response as well as cell proliferation and 
migration were enriched at time of diagnosis (Table S26). The participant’s gut microbiome 
Shannon diversity also changed with time (p = 0.0041), primarily declining in the two years 
prior to diagnosis, with a nadir at diagnosis (Fig. 5f) and increasing with treatment. Outlier 
microbes (95 percentile) at time of diagnosis included low proportions of the genera 
Clostridium IV, Lachnospiraceae incertae sedis, unclassified Clostridiales and 
Ruminococcaceae and elevated proportions of the class Gammaproteobacteria (Table S25). 
Similar to our findings in participants with low diversity prior to DM diagnosis, at the point 
of lowest diversity, the phylum Bacteroides predominated (84%). Altogether, we 
demonstrate that longitudinal molecular outlier analysis can identify deviations in key 
molecules associated with disease to reveal potential biomarkers and give insights into 
underlying biological mechanisms associated with the disease.
Hematologic, immune & infection profiling—Comprehensive clinical labs identified 
many important health-related findings. Thirty participants had hemoglobin or hematocrit in 
the anemic range, including 28 participants without prior known anemia (Hemoglobin: 
Males <13.5 g/dL, Females <11.7 g/dL). In participants with anemia, mean corpuscular 
volume (MCV) was low (< 82 f/L) in 26.7% (n = 8) suggesting microcytic anemia, 10% (n = 
3) had an elevated MCV (> 98 f/L) with normal mean corpuscular hemoglobin concentration 
and the remainder had normocytic anemia. Importantly, one of these participants was 
discovered to have alpha thalassemia trait after referral to their physician for anemia 
evaluation.
Immunological profiling with IgM, identified one participant with a significantly elevated 
IgM (Fig. 5g) which led to a clinical diagnosis of monoclonal gammopathy of undetermined 
significance (MGUS). Nine participants were noted to have persistently low IgM (2 or more 
IgM < 30 mg/dL). Four participants had subsequent clinical evaluation of IgA and IgG 
Rose et al. Page 10
Nat Med. Author manuscript; available in PMC 2019 November 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
which led to identification of IgG monoclonal gammopathy and subsequent diagnosis of 
smoldering myeloma in one participant. The discovery of MGUS and smoldering myeloma 
precancers has important implications in elevated risk and screening for cancer56,57.
During the study, wearable monitoring detected temperature and heart rate abnormalities 
related to inflammatory disturbances as measured by hsCRP (n = 4). In one of the 
participants, these findings resulted in diagnosis of Lyme disease2. Thus, important health 
information related to hematologic, immune and infection systems were revealed by a 
variety of different approaches.
Effect of iPOP Participation on Participants
The deep phenotyping profiling had an effect on the majority of the participants by (a) 
encouraging appropriate risk-based screening including genetic counseling, (b) facilitating 
clinically meaningful diagnosis, (c) potentially informing therapeutic choices (mechanistic 
or pharmacogenomic information), and (d) increasing awareness leading to diet and physical 
activity modifications. Overall, we found over 67 major clinically actionable health 
discoveries spanning various area including metabolic, cardiovascular, heme/oncological and 
infectious using standard clinical, enhanced, and emerging technologies (Fig. 6a, Table S2).
Fifty-eight participants were surveyed mid to late study about the effect of participating in 
the study including changes on food and exercise habits, health findings, and their sharing of 
results with their personal doctors, family and others. Eighty-two percent reported some 
change in diet and/or exercise habits (Fig. 6b). In addition, almost half reported changing 
other health behaviors as a result of the study, including improving sleep, reducing stress, 
adding fiber and supplements to their diet, more careful self-examinations, recording food 
intake, attending a fitness camp and general lifestyle changes (Table S27). Fig. 6c shows the 
amount of change in diet and exercise. Participants also reported that their wearable device 
kept them accountable for exercising and more mindful to take walking breaks. Others 
reported using wearables to monitor sleep.
The majority of participants had discussed study results with their family (71%) and 
physicians (68%). Physician discussions led to follow-up testing in 29% of the cases. 
Additional testing included having children tested for gene mutation, colonoscopy, 
additional eye exams, cardiac calcium scan, PET scan to evaluate lymphoma, repeating 
study tests (echocardiogram, pulmonary function tests) in the clinical setting, extra screening 
for macular degeneration risk, and additional tests for diabetes-related studies (SSPG and the 
Quantitative Sudomotor Axon Reflex Test). Participants were also asked about the effect of 
SSPG testing and CGM monitoring (Table S28). Eight participants who used a CGM 
monitor reported that it helped them make different dietary and meal frequency choices to 
reduce their blood sugar spikes. SSPG results motivated at least 2 participants to change 
their activity and diet and were reassuring to others. Therefore, overall, a myriad of positive 
behavior modifications and follow-up tests resulted from study participation.
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Discussion
Our study found that combining untargeted multi-omics and physiological longitudinal 
profiling with targeted profiling of metabolic and cardiovascular risk led to actionable health 
discoveries and meaningful physiological insights building on our previous work3. Our 
targeted profiling approach enabled us to connect longitudinal profiling of glucose 
metabolism with multi-omics profiling facilitating the precision medicine goal of defining 
diseases based on molecular mechanisms and pathophysiology1. The untargeted longitudinal 
big data approach led to a number of discoveries in other areas such as cardiology, oncology, 
hematology and infectious disease, indicating that broad profiling is valuable for disease 
detection in many different areas. We capitalized on the depth of longitudinal profiling to 
identify deregulated molecules and pathways associated with the transition from health to 
disease.
The study informed more than half the participants of their preDM and DM status, 
dyslipidemia, and hypertension, which led many to institute diet and physical activity 
lifestyle changes. Our enhanced clinical assays including OGTT, beta-cell function 
assessment, insulin resistance and CGM in combination with standard clinical tests (FPG 
and HbA1C) improved characterization of preDM and DM status. Importantly, the in-depth 
physiological profiling identified individual mechanisms of glucose dysregulation which has 
important implications for implementation of personalized treatments. Our findings are 
consistent with the recent study which found that treatments based on the current 
classification are not well tailored to mechanistic subtypes58 and proposed 5 subtypes of 
adult onset DM. Deeper molecular understanding of progression to DM and its 
characteristics in the individual may help tailor therapy to its underlying pathophysiology 
and will likely identify additional subtypes and also inform stratification of CVD risk59. The 
superiority of using multi-omics data for SSPG prediction compared to standard measures 
illustrates the value of multi-omics data to help provide a molecular taxonomy of disease1, 
as well as replace expensive burdensome tests for insulin resistance with a simple blood test. 
Microbiome measures were also a good predictor of SSPG when combined with clinical 
measures and SSPG inversely correlated with Shannon diversity further demonstrating the 
intricate relationship between gut microbes and insulin resistance consistent with our multi-
omics study of weight gain60.
Although the majority of our exome sequencing findings were in the oncologic realm, 
several important metabolic exome findings were found including a MODY mutation with 
implications for medication management, a RBM20 mutation related to dilated 
cardiomyopathy and numerous pharmacogenomic variants that have important health 
implications61. Furthermore, two participants experienced vascular events, unaware of 
relevant pharmacogenomics information which could have suggested alternative treatments. 
Thus, we expect complex genetic risk assessment such as the information learned in this 
study to be incorporated into risk management and tailored treatment of disease62.
Imaging plays a central part in precision health initiatives allowing the early detection of 
oncological and systemic disease63. In our study, imaging helped detect dilated 
cardiomyopathy (in the RBM20 patient), early-stage atherosclerotic disease and a case of 
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asymptomatic lymphoma. Wearable sensors are emerging as a transformative technology for 
precision health and medicine and heart rate monitoring led to the diagnosis of atrial 
fibrillation, sleep apnea and detection of Lyme disease in participants. Large population-
based initiatives such as “myHeart counts” are evaluating the potential of wearable heart 
sensors to detect subclinical atrial fibrillation7 and electrocardiographic monitoring is now 
available in consumer wearable devices64. Our findings also suggest a role for CGM in 
diabetes prevention by identifying unrecognized glucose dysregulation6, and enabling 
individual to optimize diet based on personalized glycemic responses.
Our multi-omics analysis also provided important insights into ASCVD risk, highlighting 
the importance of systemic inflammation. Although our study was not powered for outcome 
analysis, all 5 participants with incident cardiovascular events had subclinical inflammation. 
Furthermore, correlation network analysis highlighted the role of monocytes, HGF, IL-2, 
MCP-3 and interferon-gamma cytokines including MIG and IP10 and other molecules in 
cardiovascular health. These analytes are involved in inflammation and are emerging in the 
context of ASCVD40-42,44,65.
Untargeted longitudinal outlier analysis of the period leading up to the diagnosis of 
lymphoma illustrates the importance of longitudinal multi-omics analysis for biomarker and 
pathway discoveries. We identified potential critical biomarkers (e.g. MIG) and changes in 
the microbiome up to 1 year prior to diagnosis demonstrating the power of monitoring 
molecules longitudinally to detect deviations from the healthy baseline. Outlier biomarkers 
at time of diagnosis illustrated deregulated pathways related to inflammation, cell 
proliferation and cell migration that shed light on underlying dysregulated biological 
mechanisms associated with the disease. Further work will be needed to streamline the 
investigation of untargeted discoveries within precision medicine research. Given the need 
for early biomarkers for cancer detection, longitudinal multi-omics analyses represent an 
important tool for meeting this need. In addition to individual molecule monitoring, omics 
profiles provide the opportunity to detect outliers relative to a matched-healthy population. 
Clinical outlier analysis identified one participant with MGUS where early diagnosis with 
follow-up can increase survival time in individuals who progress to an associated 
malignancy56. While some omics outlier profiles could be clearly connected to an 
underlying health condition, the case of the participant with significant RNA-seq outliers 
illustrates the challenges of interpreting the clinical relevance of outlier analysis results with 
emerging measures. While precision medicine approaches have the potential for unnecessary 
anxiety and overtesting, we did not observe this in our population.
In the rapidly evolving field of precision medicine, this study should be assessed in the 
context of methodological considerations. Our cohort comprised highly educated volunteers, 
and therefore likely had a self-selection bias. Although this may affect the generalizability of 
our findings for behavioral changes, it is less likely to affect the underlying biological 
associations of multi-omics with glucose measures. A study strength is its ethnic diversity, 
which is greater than other longitudinal multi-omics studies4,5. We demonstrate the 
feasibility of a longitudinal precision health and medicine approach that builds on sound 
molecular and physiological phenotyping. We show that in-depth physiological and multi-
omics characterizations is likely to further refine risk stratification. The intensive 
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longitudinal study design demonstrates how a small longitudinal cohort can yield important 
health and discovery findings. In the future, it will be possible to design personalized testing 
programs based on individual disease risk and longitudinal marker trajectories as well as 
evaluate the cost-value of these approaches for individuals and health care systems.
Data Availability
Raw omics data (transcriptome, immunome, proteome, metabolome, microbiome) included 
in this study are hosted on the NIH Human Microbiome 2 project site (https://
portal.hmpdacc.org/) under the T2D project along with clinical laboratory data through 
2016. Data from participants who have not consented to make their data public are available 
on dbGAP (accession phs001719.v1.p1). Additional data unique to this manuscript has been 
provided in supplemental data files.
Online Methods
Participant Consent and Accrual
Participants were recruited from the Stanford University surrounding community with the 
goal of enriching the cohort with individuals at risk for Type 2 diabetes and thus included 
individuals who expressed interest in other studies related to diabetes. Participants were 
enrolled as part of Stanford’s iPOP (Integrated Personal Omics Profiling) research study 
(IRB 23602), which entails longitudinal multi-omics profiling of a cohort of adult volunteers 
enriched for pre-diabetes. There was no payment required to participate in the study and 
participants were not paid for their time. This study is part of the NIH integrated Human 
Microbiome Project (iHMP).
Design, Setting and Participants
The iPOP study is a longitudinal prospective cohort study68 containing 109 individuals 
(Extended Data Figure S1a). Inclusion criteria were ages 25 to 75, body mass index (BMI) 
between 25 and 40 kg/m2 and 2-hour oral glucose tolerance test in the normal or prediabetic 
range (< 200 mg/dl). Exclusions included active eating disorder, hypertriglyceridemia > 400 
mg/dL, uncontrolled hypertension, heavy alcohol use, pregnancy/lactation, prior bariatric 
surgery, and active psychiatric disease. After meeting initial recruitment goals, we expanded 
our inclusion criteria to include people with diabetes and people with normal BMI into the 
study. Participant demographics are summarized in Table 1 with detailed data provided in 
Tables D1, D2 and D3. Of note our cohort is slightly different than the main iHMP paper 
(Zhou et al., submitted). We excluded one participant who had no clinical history or follow-
up information available and included 4 participants with clinical discoveries who entered 
the study after 2016 and thus had no omics data available.
The cohort was recruited over a number of years with the first participant starting in 2010. 
The study design has been described in detail previously68. Briefly, participants were asked 
to donate samples (i.e. fasted blood and stool) quarterly when healthy and more frequently 
when sick (viral infection), after immunization and various other events such as after taking 
antibiotics and going through colonoscopy. Samples collected through December 2016 were 
used for multi-omics analysis and corresponds to a median participation duration of 2.8 
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years. Standard and enhanced clinical lab data and participant surveys were available 
through June 2018. Most analysis were performed using healthy time points only. It is 
detailed in the text if all time points were used.
Measurements
All blood samples were collected after an overnight fast and were used to perform standard 
and enhanced clinical tests as well as emerging assays (Fig. 1). Standard tests included: 
FPG, HbA1C, fasted insulin, basic lipid panel, complete metabolic panel, CBC with 
differential and others (Table S1). In addition, participants were asked to complete various 
surveys in relation to demographics and current and past medical history, medications, 
smoking history, and family history, anthropometry, diet and physical activity as well as 
stress. Enhanced tests included: OGTT, SSPG, beta-cell function assessment, hsCRP, IgM, 
cardiovascular imaging (echocardiography, vascular ultrasound), cardiopulmonary exercise, 
CVD markers and wearable devices (physiology and activity monitor, continuous glucose 
monitoring (CGM)). In addition, multi-level molecular profiling were performed (emerging 
tests) including genome, gene expression (transcriptome), immune proteins (immunome), 
proteins (proteome), small molecules (metabolome), and gut microbes (microbiome). 
Clinical laboratory measures, immune proteins and cardiovascular biomarkers are detailed in 
Table S1. Participant surveys included the International Physical Activity Questionnaire, 
Stress and Adversity Inventory, and Perceived Stress Scale-1069-71.
Modified Insulin Suppression Test
Sixty-nine participants underwent the modified insulin suppression test72 to determine 
steady-state plasma glucose (SSPG) levels. The test was performed after an overnight fast 
and consists of 180-minute infusion of octreotide (0.27μg/m2/min), insulin (0.25 μg/m2/
min), and glucose (240 μg/m2/min) with blood draws at minutes 150, 160, 170, and 180. 
The oximetric method was used to determine blood glucose and steady-state plasma glucose 
(SSPG) was determined by taking the mean of the four measurements. Reasons for not 
participating in this test included medical contraindications (n = 9), refusal (n = 5) and 
dropped out of study (n = 11) and not yet performed (n = 15).
Multi-omics Measures
Detailed methods regarding sample preparation, data acquisition and data preprocessing are 
available in the main NIH integrated Human Microbiome Project study by Zhou et al 
(submitted). We briefly summarize these methods here.
Genomics—Whole Exome Sequencing (n = 88) was performed by an accredited facility 
and variant calling was performed using an in-house pipeline (HugeSeq)73. Exomes were 
assessed for pathogenic variants according to the American College of Medical Genetics 
Guidelines11,74. The Online Mendelian Inheritance in Man (OMIM) database was used. 
Further details on processing and variant calling are provided in Rego et al.11
Peripheral Blood Mononuclear Cell (PBMC) RNA Sequencing—RNA sequencing 
from bulk PBMCs was performed using the TruSeq Stranded total RNA LT/HT Sample Prep 
Kit (Illumina) and sequenced on Illumina HiSeq 2000 instrument. The ‘TopHat’ package75 
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(v. 2.0.11) in R (v. 3.4) was used to align the reads to personal genomes, followed by 
‘HTseq’ (v. 0.6.1) and ‘DESEQ2’76 (v. 3.5) for transcript assembly and RNA expression 
quantification.
Plasma SWATH-Mass Spectroscopy Proteomics—A NanoLC 425 System (SCIEX) 
was used to separate tryptic peptides of plasma samples. MS analyses were performed with 
randomized samples using SWATH Acquisition on a TripleTOF 6600 System equipped with 
a DuoSpray Source and 25 μm I.D. electrode (SCIEX). A final data matrix was produced 
with 1% FDR at peptide level and 10% FDR at protein level. Protein abundances were 
computed as the sum of the three most abundant peptides (top3 method). To address batch 
effects, subtraction of the principal components showing a major batch bias was performed 
using Perseus (v. 1.4.2.40).
Immune Protein Measurements—The 62 plex-Luminex antibody-conjugated bead 
capture assay (Affymetrix) was used to characterize blood levels of immune proteins. The 
assay was performed by the Stanford Human Immune Monitoring Center. The protocol is 
available at:http://iti.stanford.edu/content/dam/sm/iti/documents/himc/protocols/
LuminexMultiplexAnalysisprotocol030213.doc (accessed May 1, 2018).
Plasma Liquid Chromatography-Mass Spectrometry (LC-MS) Metabolomics—
Untargeted plasma metabolomics was performed using a broad spectrum LC-MS platform77. 
This analytical platform has been optimized to maximize metabolome coverage and involves 
complementary reverse-phase liquid chromatography (RPLC) and hydrophilic interaction 
liquid chromatography (HILIC) separations. Data were acquired on a Q Exactive plus mass 
spectrometer (Thermo Scientific) for HILIC and a Thermo Q Exactive mass spectrometer 
(Thermo Scientific) for RPLC. Both instruments were equipped with a HESI-II probe and 
operated in full MS scan mode. MS/MS data were acquired at various collision energies on 
pooled samples. LC-MS data were processed using Progenesis QI (Nonlinear Dynamics) 
and metabolic features were annotated by matching retention time and fragmentation spectra 
to authentic standards or to public repositories. Some metabolites elute in multiple peaks and 
are indicated with a number in parenthesis following the metabolite name ordered by elution 
time.
Plasma Lipidomics—Lipids were extracted and analyzed as previously described78. 
Briefly, we used a mixture of MTBE, methanol and water to extract lipids from 40 μl of 
plasma following biphasic separation. Lipids were then analyzed with the Lipidyzer 
platform consisting in a DMS device (SelexION Technology, SCIEX) and a QTRAP 5500 
(SCIEX). Lipids were quantified using a mixture of 58 labeled internal standards provided 
with the platform. Lipodomics data is provided in Table D4.
16S Microbiome Sequencing—DNA was extracted from stool in line with the Human 
Microbiome Project’s (HMP) Core Sampling Protocol A (hmpdacc.org). Targeted rRNA 
gene amplification of the V1 through V3 hypervariable regions of the 16S rRNA gene was 
performed using primers 27F and 534R (27F:5’-AGAGTTTGATCCTGGCTCAG-3’ and 
534R: 5’- ATTACCGCGGCTGCTGG-3’), and subsequently sequenced using 2×300 bp 
paired-end sequencing (Illumina MiSeq). Illumina’s software handles initial processing of 
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all the raw sequencing data. A standard of one mismatch in primer and zero mismatch in 
barcode was applied to assign read pairs to the appropriate sample within a pool of samples. 
Barcodes and primers were removed prior to analysis. Amplicon sequences were clustered 
and Operational Taxonomic Units (OTU) picked by Usearch against GreenGenes database 
(May 2013 version) and final taxonomic assignment were performed using RDP-classifier.
ASCVD Circulating Markers
Millipore immunoassays human cardiovascular disease panels 1 to 4 (HCVD1MAG-67K, 
HCVD2MAG-67K, HCVD3MAG-67K, HCVD4MAG-67K) were used to characterize 
blood ASCVD circulating markers. The assays were performed by the Stanford Human 
Immune Monitoring Center.
Wearable Physiology and Activity Monitoring
Participants wore a Basis watch during the first part of the study and a Fitbit Charge 2 during 
the latter part of the study. We developed a special algorithm, “Change of Heart” to detect 
abnormalities in heart rate relative to a person’s baseline which was shown to provide an 
early warning signal of clinical abnormalities and disease which is described in detail in Li 
et al2.
Continuous Glucose Monitoring
Continuous glucose monitoring (CGM) was performed with the Dexcom G4 CGM system. 
Participants wore the monitors for 2–4 weeks with interstitial glucose concentrations 
recorded every 5 minutes. They were also given glucose meters (AccCheck Nano 
SmartView) to measure finger prick blood glucose concentrations twice a day for the 
purpose of calibration.
Echocardiography
Baseline rest echocardiography was performed using commercially available echo systems 
(iE33; Philips Medical Imaging, Eindhoven, the Netherlands). Post-stress images were 
acquired immediately post-exercise, as per international consensus. Digitized 
echocardiographic studies were analyzed by the Stanford Cardiovascular Institute Biomarker 
and Phenotypic Core Laboratory on Xcelera workstations in accordance with published 
guidelines of the American Society of Echocardiography79. Regarding specific 
echocardiographic variables, left ventricular ejection fraction (LVEF) was calculated by 
manual contouring of apical imaging80. Left ventricular global longitudinal strain (LV GLS) 
was calculated from triplane apical imaging on manual tracings of the mid wall with the 
formula for LaGrangian Strain % = 100 x (L1 - L0)/L0), as previously described81. With 
tissue Doppler imaging, we used peak myocardial early diastolic velocity at the lateral mitral 
annulus and the assessment of trans mitral to tissue Doppler imaging early diastolic velocity 
ratio (E/e’)82,83.
Vascular Ultrasound
Screening for subclinical atherosclerosis was performed using vascular ultrasound of the 
carotid and femoral artery using a 9.0 MHz Philips linear array probe and iE33 xMATRIX 
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echocardiography System manufactured by Philips (Andover, MA, USA). Vascular stiffness 
was assessed using central pulse wave velocity (PWV).
Cardiopulmonary Exercise Testing
Symptom-limited cardiopulmonary exercise (CPX) ventilatory expired gas analysis was 
completed with an individualized RAMP treadmill protocol84. Participants were encouraged 
to exercise to maximal exercise capacity. In addition, we monitored the respiratory exchange 
ratio (RER) during exercise and considered an RER ratio < 1.05 as representing sub-optimal 
or limitations associated with fatigue. Ventilatory efficiency (VE), oxygen consumption 
(VO2), volume of carbon dioxide production (VCO2) and other CPX variables were acquired 
breath by breath and averaged over 10 second intervals using CareFusion Oxygen Pro (San 
Diego, California) or CosMEd Quark (Rome, Italy) metabolic system. VE and VCO2 
responses throughout exercise were used to calculate the VE/VCO2 slope via least squares 
linear regression (y = mx + b, m = slope)85. Percent predicted maximal oxygen consumption 
was derived using the Fitness Registry and the Importance of Exercise: a National Database 
(FRIEND) registry equation, derived from a large cohort of healthy US individuals who 
completed cardiopulmonary exercise testing86.
iPOP Participant Surveys
Participants completed a survey on how the study had impacted their eating and exercise 
habits, what they learned about their health during the study, whether they discussed findings 
with their doctor, any follow-up testing, and other people they shared data with. This survey 
was initially administered anonymously but we then switched to surveys identified by 
participant ID. The quantitative results reported in Fig. 6 are from all participants who filled 
out an identifying survey (using last filled out survey where there were more than one). We 
used participant comments from anonymous and identified surveys in Table S27. At each 
quarterly visit, participants were asked about changes to health and medication. Participants 
were also asked by the study dietician how iPOP participation and CGM monitoring 
impacted their health behaviors (Table S28).
Calculation of Insulin Secretion Rate and Disposition Index
We used the ISEC program87 to calculate the insulin secretion rate (ISR) from deconvolution 
of c-peptide measurements from plasma sampled at various time points during the OGTT (at 
minutes 0, 30 and 120). The deconvolution method uses population-based kinetic 
parameters14 for c-peptide clearance to estimate insulin secretion rates at other timepoints. 
ISR was reported in pmol/kg/min at every 15-minute time interval between 0 and 120 
minutes. The disposition index (DI) was calculated as the ISR at 30 minutes (ISR30) times 
the Matsuda index, which was calculated as in Cersosimo et al13. DI was reported as 
(pmol/kg/min)/(mg/dL*μU/mL).
Cluster Analysis and Association of Disposition Index with Multi-omics Measures
Insulin secretion rates were row standardized across the 9 timepoints from an OGTT sample 
and then clustered via the k-means clustering algorithm in R (v. 3.5) (function ‘kmeans’), 
with k = 4. Simple linear models were used to associate the disposition index with each 
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multi-omics analyte. Values for multi-omics analytes were from the time point closest to the 
OGTT date. Adjustment of p-values for multiple testing was performed using the 
Benjamini-Hochberg method, with an adjusted p-value of < 0.10 used to identify analytes 
significantly associated with the disposition index.
ASCVD and Adjusted ASCVD Risk Score Calculation
The ASCVD Pooled Cohort Risk Equations were implemented according to the instructions 
in the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk33, using SAS 
9.4 statistical software. The baseline time point was used for all participants except those 
that turned 40 during the study. In these cases, the first time point after age 40 was chosen. 
Participants under the age of 40 (n = 7) for the entire duration of the study were assigned the 
age of 40 for the purposes of ASCVD risk score calculation. To calculate the optimal risk for 
someone of a particular, age, sex and race, we used total cholesterol of 170, HDL of 50, and 
systolic blood pressure of 110 with no blood pressure medications, diabetes, or smoking. 
Adjusted ASCVD risk score was calculated by subtracting the optimal ASCVD risk score 
for a person of the same age, gender and race, from the participant’s ASCVD risk score.
Association of Multi-omic Analytes and Adjusted ASCVD Risk Score
First, a median value was calculated for each analyte in each participant using healthy time 
points. A minimum of three healthy visits per participant was required. Spearman 
correlations were then calculated between adjusted ASCVD risk score and the median value 
of each multi-omics analyte. Associations were considered significant for analytes with q-
value < 0.2. FDR correction was performed using the ‘qvalue’ package (v. 1.36.0) in R (v. 
3.0.1).
Correlation Network Analysis
Spearman correlations among molecules significantly associated with disposition index and 
adjusted ASCVD risk score were calculated using the rcorr function in the ‘Hmisc’ package 
(v. 3.15–0) in R (v. 3.0.1) and p-values were corrected for multiple hypothesis using 
Bonferroni. Correlation networks were plotted using the R package ‘igraph’ (v. 0.7.1) and 
the layout used was Fruchterman-Reingold. Edges represent correlations with Bonferroni-
corrected p-value < 0.05 and 0.10 for the disposition index and ASCVD risk score, 
respectively.
Linear Mixed Models (healthy-baseline and dynamic models)
SAS 9.4 Proc Mixed was used to perform linear mixed model analysis using the full 
maximum likelihood method of estimation and the between-within method for estimating 
degrees of freedom. We used a random intercept model with an unstructured covariance 
matrix for all analytes. Since linear time explained only a small amount of within person 
variation in FPG (1.2%) and HbA1C (5.0%) at healthy timepoints, we did not include time 
in our models. The outcome measures (FPG, HbA1C and hsCRP) were log-transformed in 
all models and the analytes were standardized to a mean of zero and standard deviation of 
one. All models were controlled for sex and age at consent. The healthy-baseline models 
used data from healthy quarterly visits. The dynamic analysis used the ratio to the first 
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available time point for each outcome measure and analytes and used all time points in the 
study. P-values were corrected for multiple hypothesis testing using the Benjamini-Hochberg 
procedure. Significant analytes have BH FDR < 0.2.
Data Reporting
In reporting results we considered consistency between models and results, validation 
through literature review of emerging molecules and relevance to disease state or risk 
condition. We also considered whether differing results varied because of sensitivity and 
variability of measures, the difference between evaluating absolute baseline values versus 
relative change, and the potential for biological saturation.
Multi-omics Outlier Analysis
Z-scores (mean of zero and standard deviation of one) were calculated after log2-
transformation for all measures in all participants and outliers were defined as absolute Z-
score > 95th percentile. Associated P-values were calculated assuming a normal distribution. 
P-values were corrected for multiple hypothesis using the Benjamini-Hochberg procedure.
Stroke Genes Outlier Analysis
Z-scores were calculated as described above for 14 of 32 genes recently identified as being 
associated with stroke and stroke types39. The 14 genes that we detected in our RNA-seq 
dataset were as follows: CASZ1, CDK6, FURIN, ICA1L, LDLR, LRCH1, PRPF8, SH2B3, 
SH3PXD2A, SLC22A7, SLC44A2, SMARCA4, ZCCHC14, ZFHX3. A composite Z-score 
was calculated by summing the individual gene Z-scores.
Pathway Enrichment Analysis
The web tool IMPaLA version 11 (build April 2018) (Integrated Molecular Pathway-Level 
Analysis) (http://impala.molgen.mpg.de) was used for the joint pathway analysis of proteins 
(from SWATH-MS) and metabolites (from LC-MS) abundances. Uniprot and HMDB 
accession numbers were used for proteins and metabolites, respectively. Pathway 
significance for proteins and metabolites separately was calculated using a hypergeometric 
test; the whole space of proteins and metabolites described in the pathways were used as a 
background. Joint p-values combining protein and metabolite pathways are calculated using 
Fisher’s method. Multiple comparisons are controlled for using the Benjamini-Hochberg 
procedure88.
Exercise Sub-study Analysis
ASCVD risk scores were calculated using cholesterol labs closest to the exercise study date 
using the same method as that used for the baseline ASCVD risk scores. Correlation analysis 
was done with ‘corrplot’ package in R (v. 3.3.2). The network was plotted using Cytoscape 
3.4.089, where edges represent correlations with statistically significant Spearman’s values 
(FDR < 0.2). False discovery rate correction was performed using the ‘qvalue’ package (v. 
1.36.0) in R. The distance between nodes represents the strength of the pull between a node 
and its connected neighbors. The larger the value, the closer the distance between the two 
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nodes. The system was iterated until dynamic equilibrium using the prefuse force directed 
layout90.
Microbiome Diversity: Univariate Models
Shannon diversity was calculated with SAS 9.4 using a code adapted from Montagna91. SAS 
9.4 Proc Mixed using restricted maximum likelihood estimation the between-within degrees 
of freedom method was used to model the association of HbA1c, FPG and SSPG and 
Shannon diversity H’ index. Preliminary analyses were done in proc gam and suggested an 
‘inverse u’ distribution for all 3 measures in relationship to the Shannon diversity index. 
HbA1C and FPG were modeled using a repeated measures model with spatial power 
covariance structure. Shannon was entered into the model as a quadratic predictor of HbA1C 
and FPG. SSPG was modeled slightly differently because SSPG was only measured once in 
participants thus models with the predictor SSPG included Shannon diversity in the random 
statement. In addition, Shannon diversity as a quadratic term did not improve model fit and 
was not significant in any SSPG models so we present only the models with Shannon as a 
linear predictor (Table 6).
Microbiome Diversity: Multivariate Model
For our multivariate model (SAS 9.4 Proc Mixed), the full maximum likelihood method of 
estimation was used to enable comparison between models. The degree of freedom method 
was the between-within method. We used an unstructured covariance matrix for the models 
presented. In addition to the models presented in Table S7, we also evaluated the effect of 
adding of baseline BMI, consent age, or metformin use to the model. None of these 
covariates added significantly to the model and thus were left out of subsequent models. In 
addition, we evaluated whether use of the Firmicutes/Bacteroidetes ratio in place of the 
phylum Bacteroidetes proportion would improve the model. However the ratio accounted for 
substantially less within person variation in Shannon diversity (10.4%) thus we kept the 
proportion of the phylum Bacteroidetes in the final model.
Modeling Individual Shannon Diversity Trajectories
We modeled the change in Shannon diversity over time for individual participants using a 
general additive model (SAS proc gam) which separates the linear and non-linear 
components of the trajectory. The F test of the model using time as a predictor of Shannon 
diversity was compared to the null model and was calculated according to SAS usage note 
32927:http://support.sas.com/kb/32/927.html (accessed March 2018).
SSPG and OGTT prediction models
Reprocessing of microbiome data—For the prediction models, the microbiome 16S 
reads were reprocessed using QIIME 292 (https://qiime2.org) and the DADA293 denoising 
plugin. The resulting read depth was 18,885 ± 11,852 (mean ± SD) following paired-end 
joining, removal of chimeric reads, and removal of samples with <7000 read depth. 
Taxonomic assignment was carried out using a naïve Bayes classifier trained on the above 
primers with the 99% 13_8 Greengenes OTU data set as reference sequences94. DADA2 
facilitates cross-study comparison by providing DNA sequences of features thus making it 
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more appropriate for prediction models which will eventually need further external 
validation95.
Feature selection—Features from multi-omics (clinical labs, transcriptome, immunome, 
proteome, metabolome, lipidome and microbiome) were standardized to zero mean with unit 
variance. Clinical laboratory (including SSPG), immunome and metabolomics data was log 
transformed prior to standardization. The variance stabilizing transformation had been used 
for RNA-seq data. The sample IDs used for each SSPG and OGTT model are provided in 
Data Tables D5-D24. We then used the ‘MXM’ R package26 (v. 0.9.7) with the Max-Min 
Parents and Child algorithm (MMPC)25 option to identify features that are parents or 
children of SSPG in a Bayesian network constructed from all the available data. The features 
selected by the algorithm are hypothesized to be direct causes or effects of SSPG in the data, 
as each feature selected are SSPG dependent when conditioned on every possible subset of 
the other features. These features provide novel information about SSPG, and thus are most 
useful for prediction. There were 41 participants with SSPG values and all multi-omics data. 
Feature selection was performed using leave-one-out cross validation, where 41 training sets 
were constructed and each training set excludes the data from a different patient. We ran the 
MMPC algorithm on each training set. Features that were identified by the MMPC algorithm 
in ≥ 20% of training sets were used as features in the model. For the OGTT predictive 
model, there was no lipidomics data available.
Ridge Regression—Ridge Regression was performed using R (v. 3.4.1). For each -ome, 
we use the sample at the closest time point that is equal or prior to the time point of the 
patient’s SSPG/OGTT measurement. We performed leave one out cross validation to 
maximize available training data. For each training set, we optimize the hyperparameter by 
performing a grid search and selecting the model that minimizes test error. The predicted 
SSPG/OGTT value is the value from the cross validation iteration in which that SSPG/
OGTT data point and its associated features are excluded from the training set. We use these 
predicted values to calculate mean square error and R2 values. The value of the 
hyperparameter used was the average of the hyperparameters which minimized test error 
during cross validation.
Ethnicity PCA Plot
Ethnicity information for 72 individuals in the study was broadly classified into the five 
1000 Genomes Project (1000GP) Consortium super-population definitions, which are 
namely African (AFR), East Asian (EAS), European (EUR), South Asian (SAS) and 
admixed American (AMR). Individuals who self-identify as Indians from South Asia were 
categorized as SAS (n = 7), Hispanics and Latinos as AMR (n = 3), East Asians as EAS (n = 
8), Caucasians as EUR (n = 50) and African Americans (n = 4) as AFR. The ethnicity 
information from the 2,504 samples, definitions of the populations and super-populations, 
and genetic information of the 1000GP were obtained from ftp://ftp.1000genomes.ebi.ac.uk/
vol1/ftp/release/20130502/ (downloaded in April 2017).
The following filters were first implemented for each individual genome for the study: (a) 
we removed indels, leaving only the SNVs, (b) we removed SNVs without the “PASS” tag, 
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(c) we kept SNVs with a minimum read depth of 1, and (d) we removed SNVs with missing 
genotypes. We then intersected the genetic loci from 72 individuals and the samples from the 
1000GP, to obtain 6,653 SNVs common to both datasets. In order to reduce the chance of 
linkage disequilibrium and dependency between SNVs due to close proximity, we further 
thin the SNV set by taking every third SNV. Finally, we have a combined set of 2,576 
samples and 2,318 SNVs that we use for PCA. We used the smartpca tool in the PLINK2 
suite to generate the PCA96.
Extended Data
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Extended Data Fig 1. Integrated personalized omics profiling cohort flow chart and genetic 
ancestry.
(a) The flow chart demonstrates recruitment and enrollment of the iPOP cohort. (b) 
Principal components analysis (PCA) plot showing the ancestries of 72 participants. The 
reference includes 2,504 samples from the 1000 Genomes Project10. Each filled circle is a 
1000GP sample, colored by the super-population of ancestral origin, namely African (AFR; 
red), admixed American (AMR; purple), East Asian (EAS; green), European (EUR; cyan) 
and South Asian (SAS; orange). Each black symbol is an individual from the study, which 
we categorized by self-reported ethnicity consistent with the 1000GP super-population 
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definitions, namely AFR (black filled circle), AMR (black filled triangle), EAS (black filled 
square), EUR (black plus sign) and SAS (a checked box). We see that the individuals in our 
study have self-reported ancestries generally clustering within the super-population 
reference panel from the 1000GP.
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Extended Data Fig 2. Comparison of diabetic metrics in categorizing individuals when 
performed at the same time and HbA1C trajectories.
(a) Overlap of Fasting Plasma Glucose (FPG) and Hemoglobin A1C (HbA1C) categories 
when simultaneously measured. FPG impaired: 100 mg/dL ≤ FPG < 126 mg/dL; diabetic 
range: FPG ≥ 126 mg/dL; HbA1C impaired: 5.7% ≤ HbA1C < 6.5%; diabetic range: 
HbA1C ≥ 6.5%. (b) Overlap of FPG and 2-Hour Oral Glucose Tolerance Test (OGTT) when 
simultaneously measured. FPG ranges as above. OGTT impaired: 140 mg/dL ≤ OGTT < 
200 mg/dL; diabetic range ≥ 200 mg/dL. (c) Longitudinal patterns of changes in 
Hemoglobin A1C (HbA1C) over time. Six different patterns could be characterized 
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including: 1- participants who remained in the normal range the entire study (Group 1, n = 
51), 2- participants who progressed from normal to prediabetic (Group 2, n = 5), 3- 
participants who went from prediabetic to normal (Group 3, n = 10), 4- participants whose 
HbA1C went back and forth from normal to prediabetic (Group 4, n = 21), 5- participants 
whose HbA1C labs were predominantly in the prediabetic range (Group 5, n = 14), and 6- 
participants whose HbA1C crossed into the diabetic range (Group 6, n = 8). The red lines 
represent the overall penalized b-spline of participants’ data in each category.
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Extended Data Fig 3. Additional individual longitudinal trajectories for diabetic measures.
Diabetic-range metrics are indicated in red. (a) Diabetic range OGTT, (b,c) Diabetic range 
FPG, (d) undiagnosed DM at study entry (HbA1C), (e) Initial abnormality HbA1C. Note 
this person had two HbA1C measurements on the same day at two different laboratories and 
was started on medication based on the higher measurement, (f) Bouncer with diabetic range 
HbA1C and OGTT, and (g) SSPG decrease with lifestyle change.
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Extended Data Fig 4. Longitudinal microbiome trajectories in diabetes.
Longitudinal weight, gut microbial Shannon diversity and phylum proportion changes in 
participants (a) ZNDMXI3 and (b) ZNED4XZ. (c) Longitudinal changes in genus 
proportion (ZNDMXI3). Microbiome outliers (95th percentile) at the latest microbiome 
sample time point in participants (d) ZNDMXI3 and (e) ZNED4XZ. Microbial abundance is 
scaled by row with low (blue) and high (red) abundance.
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Extended Data Fig 5. Multi-omics of glucose metabolism and inflammation.
(a) Proteins and metabolites associated with HbA1C, FPG, and hsCRP using healthy-
baseline and dynamic linear mixed models. Healthy-baseline models (HbA1C n = 101, 
samples 560; FPG n = 101, samples 563; hsCRP n = 98, samples 518) account for repeated 
measures at healthy time points. Dynamic models are similar models except that analytes are 
normalized across individuals to the first measurement and all time points in the study are 
used (HbA1C n = 94, samples = 836; FPG n = 94, samples = 843; hsCRP n = 92, samples 
777). Individual analyte p-values were determined using a two-sided t-test. Multiple testing 
correction was performed and molecules were considered significant when BH FDR < 0.2. 
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Model estimates were normalized in each condition so the maximum value equal 1 and the 
minimal value equal −1. (b) Integrative pathway analysis using IMPaLa (http://
impala.molgen.mpg.de) of proteins and metabolites associated with HbA1C (n = 101, 
samples 560), FPG (n = 101, samples 563), and hsCRP (n = 98, samples 518) as determined 
by the healthy-baseline models (BH FDR < 0.2 at molecule level which matched to known 
pathways. Significance of pathways for proteins and metabolites separately is determined by 
the hypergeometric test (one-sided) followed by Fisher’s combined probability test (one-
sided) to determine combined pathway significance (BH FDR < 0.05; n’s of proteins and 
metabolites for each pathway are provided in Tables S9, S11, S13).
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Extended Data Fig 6. Outlier Analysis of RNA-seq data.
(a) Number of outlier RNA molecules (95th percentile) in each participant. Outlier analysis 
was performed on Z-scores calculated on the median expression level of each gene at 
healthy visits in individuals with at least 3 healthy visits (n = 63). The box is defined as 25th 
and 75th quartile. The upper whisker extends to 1.5 times the interquartile range from the 
box and the lower whisker to the lowest data point. The horizontal bar in the box is the 
median value. (b) Selected clinical lab and metabolite trajectories (7 measurement time 
points) for participant ZJTKAE3 showing a concomitant increase of bile acids and glutamyl 
dipeptides with ALT (alanine aminotransferase) and AST (aspartate aminotransferase).
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Extended Data Fig 7. Multidimensional cardiac risk assessment.
(a) Distribution of ASCVD risk scores (n = 35, 36 measurements) and cardiovascular 
imaging and physiology measures that have been established as cardiovascular risk markers. 
(Abbreviations: RWT-relative wall thickness, LV GLS-left ventricular global longitudinal 
strain, E/e’ - ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular 
velocity (e'), PWV-pulse wave velocity). Please note that thresholds for PWV are age-
related. Box plots were derived to display quartiles (Q1, median, Q3) with the upper whisker 
being Q3 plus 1.5*(interquartile range) and the lower whisker extending to Q1 minus 
1.5*(interquartile range) or the lowest data point. (b) Ultrasound of carotid plaque (6 
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participants of 36 had an ultrasound finding of carotid plaque) and relative distribution of 
ASCVD risk score, HbA1C and LV GLS in function of presence or absence of carotid 
plaque (Student’s t-test (two-sided) was used to evaluate differences between groups; n = 35, 
36 measurements). Error bars represent one standard deviation from the mean (upper edge of 
box). (c) Correlation network of selected metrics collected during cardiovascular assessment 
which associated (Spearman correlation (two-sided) with ASCVD risk score (q-value < 0.2); 
n = 35 participants with 36 measurements. (d) Composite Z-score of ZOBX723 (unstable 
angina with stent placement) and ZNED4XZ (mild stroke with full recovery and transition 
to diabetes). For ZOBX723, day 829 occurred 3 weeks post stent placement. Day 679 was a 
mid-infection time point. For ZNED4XZ, day 699 was the time point prior to the 
participant’s transition to diabetes and day 846 was the first diabetic time point. The stroke 
occurred on day 307 for this individual. Gray dots represent Z-scores of other participants 
(n=101 with 859 samples). (e) Violin plot showing the same data as (d) (n = 101 with 859 
samples). The box plot shows the 1st (lower edge of box), median (middle line) and 3rd 
(upper edge of box) quartiles. The upper whisker is the 3rd quartile + 1.5*(interquartile 
range) and the lower whisker is the lowest data point.
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Figure 1. Study design and data collection.
Overview of the in-depth longitudinal phenotyping used to determine health risk and status. 
Data types were categorized as: Standard (Blue), Enhanced (Purple) and Emerging (Red) 
tests. PBMCs: peripheral blood mononuclear cells; HbA1C: glycated hemoglobin; OGTT: 
oral glucose tolerance test; SSPG: steady-state plasma glucose; CBC: complete blood count; 
hsCRP: high sensitivity C-reactive protein; CVD: cardiovascular disease.
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Figure 2. Clinical and enhanced phenotyping of glucose metabolism, insulin production and 
resistance.
(a) Transitions in diabetes mellitus (DM) status (n = 109). 1st column: Self-reported DM 
status; 2nd column: DM status determined by self-report; medical records and study entry 
diabetes-related laboratory measures: FPG, HbA1C and OGTT; prediabetic range (100 
mg/dL ≤ FPG < 126 mg/dL or 5.7% ≤ HbA1C < 6.5% or 140 mg/dL ≤ OGTT < 200 mg/
dL); diabetic range (FPG ≥ 126 mg/dL or HbA1C ≥ 6.5% or OGTT (2-hour) ≥ 200 mg/dL); 
3rd column: DM history and status determined by the initial report and diabetes-related 
laboratory measures over the course of the study. For FPG to be considered impaired or 
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diabetic, two values in these ranges were required over the course of the study, whereas for 
HbA1C and OGTT only one value was required. (b) Overlap of diabetic range labs by 
participants over the course of the study. Diabetic ranges are as in panel (a). (c) Violin plots 
showing insulin levels during OGTT at 0, 30 and 120 minutes, SSPG (steady-state plasma 
glucose, n = 43 participants) and glucose disposition index (n = 89 samples from 61 
participants) by glycemic status determined by OGTT including normoglycemic, impaired 
fasting glucose only (IFG only: FPG ≥ 100 mg/dL), and impaired glucose tolerance (IGT: 
OGTT ≥ 140 mg/dL). SSPG was measured using the modified insulin suppression test. The 
disposition index was calculated as the insulin secretion rate at 30 minutes times the 
Matsuda index (pmol/kg/min). A two-sided Wilcoxon t-test was used for differential 
analysis. The violin plots illustrate kernel probability density (i.e. the width represents the 
proportion of the data) and the horizontal bar depicts the median of the distribution. (d) 
Heatmap showing insulin secretion rates which were row-standardized and clustered using 
k-mean clustering (n = 89 samples from 61 participants). Observations within clusters were 
ordered by OGTT status. OGTT status, disposition index (DI), SSPG and insulin secretion 
rate max (ISR) are indicated on the left side of the heatmap. (e) Correlation network of 
multi-omics measures associated with the glucose disposition index (n = 89 samples from 61 
participants; Benjamin-Hochberg FDR < 0.1). Correlations were calculated using Spearman 
correlation and considered significant if Bonferroni FDR < 0.05. Only networks containing a 
minimum of three molecules were plotted.
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Figure 3. Longitudinal individual phenotyping and multi-omics of glucose metabolism and 
inflammation.
Longitudinal diabetic measures demonstrating different patterns of DM onset and 
progression with (a) initial abnormality response to glucose load (OGTT), (b) initial 
abnormality in fasting glucose metabolism (FPG) and (c) initial improvement followed by 
progression. Diabetic-range metrics are indicated in red. (d) Clinical markers and immune 
proteins associated with HbA1C, FPG, and hsCRP using healthy-baseline and dynamic 
models. Healthy-baseline models are linear mixed models that take into account repetitive 
measures across participants (HbA1C n = 101, samples 560; FPG n = 101, samples 563; 
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hsCRP n = 98, samples 518). Dynamic models are similar models except that analytes are 
normalized across individuals to the first measurement and all time points in the study are 
used (HbA1C n = 94, samples = 836; FPG n = 94, samples = 843; hsCRP n = 92, samples 
777). Each analyte was modeled separately and the two sided t-test was used to determine p-
value for each analyte effect. Multiple testing correction was performed and molecules were 
considered significant when Benjamin-Hochberg (BH) FDR < 0.2. Model estimates were 
normalized in each condition so the maximum value equal 1 and the minimal value equal 
−1. (e) Integrative pathway analysis using IMPaLa66 of proteins and metabolites associated 
with HbA1C (n = 94, samples = 836), FPG (n = 94, samples = 843), and hsCRP (n = 92, 
samples 777) as determined by the dynamic models (BH FDR < 0.2 at molecule level). 
Significance of pathways was determined by the hypergeometric test (one-sided) followed 
by Fisher’s combined probability test (one-sided) to determine combined pathway 
significance (BH FDR < 0.05). The n’s of proteins and metabolites for each pathway are 
provided in Tables S15, S17 and S19. (f) Molecules selected in steady-state plasma glucose 
(SSPG) and oral glucose tolerance test (OGTT) prediction models and associated 
coefficients. For SSPG prediction, lipidomics data were used in addition to the multi-omics 
measures. MSE: mean square error.
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Figure 4. Clinical longitudinal cardiovascular health profiling and multi-omics correlation 
network of adjusted ASCVD risk.
(a) Distribution of ASCVD risk scores and adjusted ASCVD risk scores (n = 108). The box 
plot shows the 1st (lower edge of box), median (middle line) and 3rd (upper edge of box) 
quartiles. The upper whisker is the 3rd quartile + 1.5*(interquartile range) and the lower 
wisker is the lowest data point. (b) Self-reported cholesterol status versus measured total 
cholesterol profiles at study entry and over the course of the study (n = 108). (c) Multi-omics 
correlation network of molecules associated with adjusted ASCVD risk score (n = 77 
participants) using Spearman correlation and multiple testing correction of q-value < 0.2. 
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Correlations between molecules were then calculated using Spearman correlation and 
considered significant if Bonferroni corrected p-value < 0.1. Only molecules belonging to 
the main network were plotted.
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Figure 5. Oncologic discoveries.
(a) Abdominal ultrasound image where a mildly enlarged spleen measuring approximately 
13 cm in craniocaudal dimension can be seen. (b) Positron emission tomography (PET) 
imaging where a large retroperitoneal mass with high fluorodeoxyglucose (FDG) and 
intensely focal hypermetabolism occupying the majority of the spleen can be seen. (c) 
Lactate Dehydrogenase (LDH) levels at time of index imaging and after starting 
chemotherapy. (d) Levels of MIG (CXCL9) demonstrating an increase starting a year prior 
to diagnosis that peaks at time of diagnosis and goes back to baseline after treatment (n=11 
samples). Benjamin-Hochberg (BH) p-value (two-sided) was calculated on MIG Z-scores 
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assuming a normal distribution across all healthy visits in the cohort (n = 601 samples). (e) 
Functional association network of outlier proteins (95th percentile) at time of diagnostic. 
This analysis was performed using the web-tool STRING67 (https://version-10-5.string-
db.org/). Edges correspond to known, predicted or other interactions. (f) Shannon diversity 
of the gut microbiome decreasing months prior to diagnosis, reaching a minimum value at 
time of diagnostic and returning to baseline after treatment (n = 11 samples). Trajectory was 
then modeled using a general additive model which separates the linear (β = −0.197, p = 
0.002 (2-sided t-test)) and non-linear (df = 3, p = 0.0112 (one-sided Chi-sq)) components. 
An F-test (one-sided) was used to compare the model including time to the null model. (g) 
IgM (Immunoglobulin M) level distribution in the cohort (n = 109, samples 1,111). 
Benjamin-Hochberg (BH) p-value (two-sided) was calculated on IgM Z-scores assuming a 
normal distribution across all visits in the cohort. Outlier visits are from a participant that 
was diagnosed with monoclonal gammopathy of undetermined significance (MGUS). The 
box plot shows the 1st (lower edge of box), median (middle line) and 3rd (upper edge of 
box) quartiles. The upper whisker is the 3rd quartile + 1.5*(interquartile range) and the 
lower wisker is the lowest data point. The diamond is the mean.
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Figure 6. Summary of major clinically actionable health discoveries and participant health 
behavior change.
(a) Summary of clinically relevant health discoveries. 67 discoveries were considered major 
and the 55 PreDM results were not included in this count. (b) Diet and physical activity 
modifications. (c) Amount of change made in diet and exercise (5-point scale was used with 
1 being no change and 5 being significant change). MODY: Maturity onset diabetes of the 
young; DM: diabetes mellitus; PreDM: prediabetes mellitus; afib: atrial fibrillation; SVT: 
supraventricular tachycardia; CV: cardiovascular; MGUS: monoclonal gammopathy of 
undetermined significance.
Rose et al. Page 49
Nat Med. Author manuscript; available in PMC 2019 November 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
